| 4.05 -0.08 (-1.94%) | 10-23 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 7.51  |
1-year : | 9.32 |
| Resists | First : | 6.43 |
Second : | 7.98 |
| Pivot price | 4.82 |
|||
| Supports | First : | 3.93 |
Second : | 3.27 |
| MAs | MA(5) : | 4.26 |
MA(20) : | 5.26 |
| MA(100) : | 8.3 |
MA(250) : | 9.09 |
|
| MACD | MACD : | -1.1  |
Signal : | -1.1 |
| %K %D | K(14,3) : | 3.6 |
D(3) : | 4.7 |
| RSI | RSI(14): 18.6 |
|||
| 52-week | High : | 18.11 | Low : | 3.93 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ CRBP ] has closed above bottom band by 17.2%. Bollinger Bands are 10.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 4.11 - 4.15 | 4.15 - 4.17 |
| Low: | 3.85 - 3.9 | 3.9 - 3.93 |
| Close: | 3.99 - 4.08 | 4.08 - 4.13 |
Corbus Pharmaceuticals Holdings, Inc. is an oncology company, which engages in research, development, and commercializing therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells, and CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. The company was founded in April 2009 and is headquartered in Norwood, MA.
Fri, 23 Oct 2026
Corbus Pharmaceuticals Holdings, Inc. Estimates – NASDAQ:CRBP - TradingView
Thu, 22 Oct 2026
Corbus Pharmaceuticals to Present Late Breaking CRB-913 Data from Canyon-1 Study at Obesity Week® 2026 - Yahoo Finance
Wed, 21 Oct 2026
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors despite losses on the day - MarketWatch
Mon, 19 Oct 2026
Corbus Pharmaceuticals Holdings Inc. stock underperforms Monday when compared to competitors - MarketWatch
Fri, 16 Oct 2026
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors on strong trading day - MarketWatch
Thu, 15 Oct 2026
Corbus Pharmaceuticals Holdings Inc. stock underperforms Thursday when compared to competitors - MarketWatch
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 19 (M) |
| Shares Float | 13 (M) |
| Held by Insiders | 1.2 (%) |
| Held by Institutions | 83.7 (%) |
| Shares Short | 3,050 (K) |
| Shares Short P.Month | 2,250 (K) |
| EPS | -6.12 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 5.48 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -53 % |
| Return on Equity (ttm) | -95.6 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -4.67 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -5.52 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -87 (M) |
| Levered Free Cash Flow | -50 (M) |
| PE Ratio | -0.67 |
| PEG Ratio | 0 |
| Price to Book value | 0.73 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.91 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|